<DOC>
	<DOCNO>NCT00543556</DOCNO>
	<brief_summary>This clinical trial patient Type 2 Diabetes test safety MK0767 . This study also see effective MK0767 lower marker glucose metabolism improve lipid profile non-HDL cholesterol compare placebo pioglitazone .</brief_summary>
	<brief_title>MK0767 Type 2 Diabetes ( 0767-012 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 Diabetes Mellitus patient age 21 75 inclusive Patient willing discontinue current therapy duration study Patient heavy drinker Patient history Type 1 diabetes and/or ketoacidosis Patient severe diabetic retinopathy , nephropathy , neuropath Patient antihyperglycemic therapy include insulin , rosiglitazone pioglitazone 2 oral agent combination within 8 week prior visit 1 Patient history , allergy , intolerance hypersensitive troglitazone , rosiglitazone , pioglitazone include history elevate liver function test , jaundice , hepatotoxicity associate treatment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>